# AK104 for Recurrent or Metastatic Vulvar Cancer

Source: https://onco.cc/trials/nct05932212/  
OnCo record `nct05932212` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Cadonilimab, Paclitaxel / nab-paclitaxel in vulvar cancer, run by Akeso, stopped early.

## Summary

AK104 for Recurrent or Metastatic Vulvar Cancer is a phase 2 interventional study registered as NCT05932212 by Akeso, with 20 participants planned, started 2023-08-25 and reached its primary completion in 2026-05-31. Interventions recorded: AK104, AK104+ Paclitaxel+Cisplatin or Carboplatin. Conditions listed: Vulvar Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: withdrawn
- Last checked: 2026-10-19
- Tags: ctgov-ingest
- Registry id: NCT05932212
- Phase: 2
- Setting: A Multicenter, Open-label, Phase II Study of AK104 in the Treatment of Recurrent or Metastatic Vulvar Cancer
- Sponsor: Akeso
- Enrolled: 20

## Notes

- Registry status on 19 October 2026: Terminated (registry record last updated 28 September 2026; primary completion reached 31 May 2026). Why stopped, in the sponsor's words: Sponsor decision.

## Sources

- ClinicalTrials.gov NCT05932212: https://clinicaltrials.gov/study/NCT05932212

## Connected records

- cancers: [HPV-associated vulvar squamous cell carcinoma](https://onco.cc/cancers/hpv-associated-vulvar-cancer/), [HPV-independent vulvar squamous cell carcinoma (p53-mutant)](https://onco.cc/cancers/hpv-independent-vulvar-cancer/), [Vulvar cancer](https://onco.cc/cancers/vulvar/)
- technologies: [Bispecific antibodies](https://onco.cc/technologies/bispecific-antibody/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Cadonilimab](https://onco.cc/drugs/cadonilimab/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/)
- companies: [Akeso](https://onco.cc/companies/akeso/)

---
JSON: https://onco.cc/api/v1/entities/nct05932212.json